Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14688547 | 0.98 | POLB (0.64) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL22425347 | 0.92 | POLB (0.56) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL9001768 | 0.91 | POLB (0.62) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL3457039 | 0.85 | ALDH1A1 (0.57) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL23839836 | 0.84 | HSD11B1 (0.58) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL3457613 | 0.84 | KMT2A (0.57) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL19881260 | 0.82 | NPC1 (0.57) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL1001922 | 0.82 | HPGD (0.62) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL14374144 | 0.82 | HPGD (0.62) | POLBKMT2AHPGDALDH1A1TSHR | |
| SCHEMBL30804750 | 0.82 | HPGD (0.50) | POLBKMT2AHPGDALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735384-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011090911-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APH1B | POLB 1570/4885KMT2A 1229/4885HPGD 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.